The Block23 Eco-system
  • People and patients give limited access to their data in exchange for tokens; also, use tokens to purchase products and services
  • Pharma and service providers buy PMX tokens with ETH and pay people for data access; also, receive tokens from people when making purchases and give out tokens to people as a loyalty reward or offer
  • 3rd party developers and researchers that use the Block23 platform for developing Deep Learning algorithm to detect patterns in cancer events; additionally research institutes who need to use the Block23 infrastructure for analyzing their data and tools for investigating results.

The first components are the ShareMyinsight (SMI) AI platform, technology and products that have been specially designed for collecting, analyzing and automating events around behavior patterns that are detected by Deep Learning algorithms. The solutions are in use by cancer research institutes and FMCG companies as well as retailers around the world.

Genomics AI for delivering precision medicine

Block23 aims to be the platform for medical researchers to access very large, well annotated, personalized data sets in order to discover ground breaking treatments and clinically useful biomarkers for some of the world’s costliest diseases by utilizing Blockhain and AI technologies.

In order to accomplish this goal, Block23 will provide free genomic scans to more than 100,000 people as well as collect medical and fitness data on an ongoing basis in order to discover causal relationships on some of the major forms of cancer.

Contact Us

General Enquiries
info@block23.me

Press Enquiries
press@block23.me

Core Team

Dr. David Kerr
Chief Strategy Officer
Professor Cancer Medicine
Oxford University

President of the EU
Society of  Oncology

Prem Couture
Chief Architect, Founder
Tech Entrepreneur

Blockchain Solutions
ShareMyInsight, 
Cyscom Ltd, Genex8

Dr. Weiyan Zhu
Clinical scientist
Shanghai Univ. hospital
China-Europe head at
Boehringer-Ingelheim, Catalent

Dr. Gualberto Ruaño
Business Development
Founder of Genomas, Founding CEO Genaissance Pharma,
pioneer in pharmacogenomics

Kasper Ditlevsen
GTM, VP Sales
Health Care, FMCG
Consulting 
KPMG
Symphony EYC

Alexander Shivarov
CTO, Blockchain Architecture
Data Science, AI, Blockchain

ShareMyInsight
Baumanskaya University

Koly Belostotsky
Deep Learning,
Ethereum Platform
Solidity engineer

CRM, ShareMyInsight,
Aplana, Baumanskaya Univ. 

Konstantine Lomakin
CFO
Head Corp. Banking
Evrofinance, Head Private
Banking Uralsib

Advisory Team

Kees Roks 
Big Pharma Engagements
CEO Novartis
Canada, Latin America
Head of Novartis Oncology
Western Europe

Prof. Havard Danielsen
Bioinformatics Lead
Director for Cancer

Genetics and Informatics,
Oslo University

Alex Borissov 
Financial Strategy
Board Member
Private Banking

Founder Finaport
Credit Suisse, AIG

Mick Yates 
Business Strategy
Board Member
Board Director, global firms

Dunnhumby, Proctor& Gamble
Professor Leeds Univ.

Dr. Sheraz Majeed
Board Member
Co-Founder Global Blockchain
Consortium, Medical Consultant NHS

Georges Al Medawar
ICO Strategy, Partnerships
Co-Founder of Omnistry,
BDO HumanIQS

Dr. Kerr, CBE MA MD DSc FRCP (Glas, Edin & Lon) FRCGP (Hon)FMedSci, contributes to Oxford University as Professor of Cancer Medicine, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. He is also Adjunct Prof of Medicine at Weill-Cornell College of Medicine, Xiamen University and the Second Military University of Shanghai.

David has an international reputation for the treatment of and research into colorectal cancer and the quality of his work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation. He has published over 400 papers and has an H-Index of 80 associated with over 25,000 citations. He has founded 3 University spin outs; COBRA therapeutics, Celleron Therapeutics and Oxford Cancer Biomarkers. He has made a significant contribution to reforming the NHS as a Founding Commissioner for Health Improvement; Chair of the National Cancer Services Collaborative, Instigator of the Department of Health’s networked approach to clinical cancer research and developed a 20 year plan for the future of the NHS in Scotland, the “Kerr Report”.

David was elected Fellow of the Academy of Medical Sciences in 2000, the European Academy of Cancer Sciences in 2006, Honorary Fellow of Royal College of General Practitioners in 2007, appointed Commander of the British Empire in 2002 by HM the Queen and was elected President of the European Society of Medical Oncology in 2010. He has established INDOX and Afrox to improve the quality of cancer care in India and Sub Saharan Africa and has served as Health Adviser to two British Prime Ministers, Tony Blair and David Cameron.

Prem Couture is the CEO and principal architect at Cyscom-ShareMyinsight (SMI), a UK technology company developing technologies using AI and machine learning for big data analytics on consumer behavior. He is the co-founder at Genex8, a biotechnology and genetic venture formed with leading European scientists at Oxford University in cancer research with over 20 patents on biomarkers that measure drug response to cancer tumour cells, with the goal to improve R& D cycles via a cutting edge, cloud based bioinformatics platform.

Prem’s experience includes IoT sensor fusion and Deep Learning and is the inventor and patent holder of a technology that speeds up the neural processing of information as generated from computer generated graphics. He has extensive experience in implementing software technologies and solutions with leading enterprises in Retail, Life Sciences, Banking and Finance and is the founder of several international internet software businesses that developed and brought to the market a comprehensive Cloud Computing Platform and applications to major IT service companies such as Hewlett-Packard.

Prem’s current focus is on a Blockchain CRM solution for retail that empowers consumers via a universal reward currency, the REV token and Block23 for breakthroughs in cancer research.

Dr. Zhu has 22 years experience of Pharma and Consumer HealthCare businesses, has been the Business head both in China and Western Europe at Boehringer-Ingelheim (BI) a Global top 20 pharmaceutical company. He is the first Greater China Country Manager in Catalent (CTLT), NYSE and chest surgeon at Shanghai Huadong hospital. He is the Founder and CEO of start-up companies in the areas of precision medicine and brings extensive management experience in managing sizable multinational business as well as being a clinical data management expert.

Dr. Zhu has founded a first Precision Medicine commercialization platform in China, established a CLIA, CAP & China standard Clinical lab to service global market and form strategic partnership with leading Bio companies in UK/US such as the Oxford University Cancer Biomarkers company and has extensive strategy development experiences at both global and local markets as well as in direct to consumer communication in consumer facing medical businesses.

Dr. Ruaño has been an innovator and entrepreneur in the biomedical industry and advocate of personalized medicine for 30 years. Dr. Ruaño is one of the leading medical experts and executives in personalized healthcare and translational genomics worldwide. He is President and Medical Director of Genomas, which he founded in 2004.

Dr. Ruaño’s continued record of scholarship and innovation in precision medicine counts over 100 publications and 12 patents as of mid-2017. He has been principal investigator of research and development grants totaling $15 M from AHRQ, NIH, NSF and DOE. In his research career, he has developed systems for DNA-guided medicine based on genomics and clinical informatics. He has pioneered physiogenomics based on multi-gene DNA markers to the diagnosis of disease and prediction of human physiological responses to a wide array of clinical treatments.

In his prior biotechnology pursuits, Dr. Ruaño served as Chief Executive Officer and Chief Scientific Officer of Genaissance, which he founded in 1997 and led to a NASDAQ public offering and to several R&D partnerships in the pharmaceutical and diagnostic industries. He obtained his B.A. degree from Johns Hopkins University, where he was elected to Phi Betta Kappa. He obtained M.D. and Ph.D. degrees from Yale University, where he was a Fellow of the NIH Medical Scientist Training Program and the Ford Foundation. At Yale, Dr. Ruaño invented the CAS System (Coupled Amplification and Sequencing) utilized for gene-guided HIV treatment (U.S. patent 5,427,911). He is one of the 28 alumni in the University’s history honored in the Yale Innovation Timeline.

Kasper is an accomplished, entrepreneurial and qualified Senior Executive in both a Corporate and Management Consultancy capacity in Health Care, FMCG and CPGsectors. Significantly experienced in operating companies with billion dollar P&L accountability and leading large multi-functional and multi-cultural teams with industry credentials across the the health care environment. Equipped with a demonstrable track record of success initiating, developing and executing sales, price, brand, and customer strategies focused on driving aggressive and sustainable revenue, margin and market share growth.

Alexander, M.S. in computer science, is a visionary data science executive with broad spectrum of domain expertise, technical knowledge, and proven success in bringing measurable added value to companies and domains (data science, operations research, machine learning, computer science, business intelligence, IoT). He has invented many synthetic metrics that work better than old-fashioned stats, especially on disparate data sets in a Map-Reduce, Hadoop environment. Alexander has developed and implemented computational biology tools and programs to support gene research activities and has generated and tested hypotheses on genome-scale data using analytical and statistical methods. Alexander has pioneered highly innovative visualization, machine learning, optimization and statistical inference solutions for pressing Healthcare and Life Science challenges using very large scale proprietary and public data sets, computing infrastructure and insights from expert Healthcare partners.

Alexander has led project teams development using Ethereum Smart Contracts written in Solidity and implemented hyper ledger solutions in the consumer sector (www.revoz.io). He has been utilizing Bigchain DB for solving Ethereum scalability issues and IOTA Tangle for sensor fusion based solutions on Blockchain.

Nikolay holds a Master’s degree of engineering and technology in the field of computer science from Baumansky Institute in Moscow with experience in implementing smart contracts and Blockchain applications. Nikolay has strong mathematical background with strong knowledge in at least one of the following fields: statistics, data mining, machine learning, statistics, operations research, econometrics, natural language processing, and/or information retrieval. In projects involving major universities, Nikolay has created models, structured data and implemented algorithms to support analysis using advanced statistical and mathematical methods from statistics, machine learning, data mining, econometrics, and operations research.

Head of Corporate Banking at Evrofinance Mosnarbank, and Deputy Head of Private Banking Uralsib. Konstantin is a professional corporate banker and independent financial advisor on a diverse range of projects, ranging from commodities to aerospace engineering. He brings with him a unique blend of multifaceted work experience in banking, private wealth management, financial analysis and sales and marketing to support the REVOZ project at all pre and post ICO stages.

Kees Roks has 30 years of international big pharma experience gained in country organizations (the Netherlands, Germany, Norway, Japan and Russia) and Regional Management (Europe, Latin America & Canada) with specific responsibilities in sales, marketing, project management, strategic planning and general management. He has in depth knowledge of all major therapeutic areas within the pharmaceutical industry and is the Head of Novartis Oncology. In this role, he is responsible for commercial development activities. Most recently, he served as Head of the Western European Cluster (WEC) for Novartis Oncology, which included the Nordics Cluster, Belgium, the Netherlands, Switzerland, Austria and Portugal. Kees is currently the head of Novartis for Canada and Latin America.

Professor Havard E. Danielsen is a geneticist with a PhD in medicine from the University of Oslo. He is the Director of the Institute for Cancer Genetics and Informatics at Oslo University Hospital (Norway) and holds positions at the Department of Informatics, University of Oslo, and at Nuffield Division of Clinical Laboratory Sciences at the University of Oxford.  Danielsen is PI of the DoMore! project, which was the winner of a prestigious Lighthouse Project grant from the Norwegian Research Council, and he also serves as a PI at the Centre for Cancer Biomedicine. His research focuses primarily on DNA- and chromatin organization, using informatics as a tool to study genomic changes in cancer.

Alex is a founding partner and Director of the Board of Finaport AG, a Swiss wealth management firm with offices in Zurich, Singapore and Miami, providing investment strategies and solutions to institutional and individual clients. Prior to Finaport, Alex worked at AIG Private Bank AG, Zurich, assuming responsibility for Private Banking in Central and at Credit Suisse managing operations in Eastern European and Asia.

Mick is an experienced Board advisor on the leadership, strategy implications and practical application of data based insights with a successful track record as senior Exec & Board Director in global firms, consultancy, start-up & non-profit. A visiting Professor at University of Leeds Business School, Mick led the team at Dunnhumby’s for creating partnerships with Clients across the world and was involved in Dunnhumby’s sale to Tesco and Kroger. Prior to Dunnhumby, Mick was Company Group Chairman (Regional CEO) of Johnson & Johnson  and at Procter & Gamble in Asia-Pacific.

Dr. Sheraz is the co-Founder Global Blockchain Consortium and works as a Medical Consultant for the NHS of UK for the past 15 years and was nominated for ‘Most Caring Individual’ at Newham General Hospital. He works in palliative medicine and as a consultant in the medical Blockchain space.

Georges is the Co-Founder of Omnistry and was the Chief Business Development officer at HumanIQ. He is actively in a wide specter of global focused n disruptive technologies. Georges is currently on a research and development project involving the study of Distributed Ledger Systems, mainly the applied uses and the resulting societal and economic implications to governance models.